The National Institutes of Health is transferring funds to the U.S. military to develop drugs and other medical tools against nuclear threats, infectious diseases and pandemic influenza, according to an agreement disclosed on Sept. 4.
The document says the NIH will send money to the Department of War’s Office of the Assistant Secretary of War to support the advanced development of medical countermeasures against pandemic influenza, chemical, biological, radiological and nuclear threats, and emerging infectious diseases. The office will use the funds to award contracts and grants to develop countermeasures such as drugs and diagnostic tests. The dollar amount was not disclosed.
An NIH spokesperson said many emerging health problems, including biological, radiological and chemical challenges, affect both civilian and military populations and that it makes sense for the two agencies to share expertise and partner on research. The spokesperson said the partnership will operate on a project-by-project basis, that all research will fall within the scope of the NIH’s mission, and that there is no blanket transfer of funds. No projects have been identified for the current fiscal year.
What the partnership covers
The categories of threats covered by the agreement, collectively referred to as CBRN for chemical, biological, radiological and nuclear, represent the highest-consequence categories of both military and public health risk. Antidotes, vaccines, treatments and diagnostics for these threats are a longstanding area of joint interest between the civilian public health establishment and the military.
The military has operational requirements for treatments that civilian medical institutions do not, including rapid deployment in battlefield conditions or administration by non-medical personnel. NIH-funded research that produces treatments usable in civilian hospitals may require adaptation for military use, and vice versa.
The Department of War acquisition role
The agreement designates the Department of War’s Office of the Assistant Secretary of War as the acquisition service provider. This means the military office will handle the contracting process, including soliciting proposals, evaluating bidders and awarding grants and contracts to developers. NIH provides the funding and mission scope while the military manages the procurement mechanics.
This structure mirrors arrangements the federal government has used in other dual-use research areas, where one agency has funding authority and mission expertise while another has acquisition infrastructure and contracting relationships with specialized developers.
The broader context
This area of development gained significant federal investment following the September 11 attacks and the 2001 anthrax letter attacks, which together produced the Bioterrorism Response and Preparedness Act of 2002 and later the Pandemic and All-Hazards Preparedness Act. The NIH and the Department of Health and Human Services have maintained CBRN programs since that period.
The involvement of the Department of War in acquisition services for this program represents a structural integration of military and civilian public health infrastructure at the contracting level.
